Opinion|Videos|December 2, 2024
Implications of Relapse and Hospitalization Rates with Rituximab Use in NMOSD Management
Author(s)Michael Levy, MD, PhD
Key Takeaways
- Rituximab shows higher hospitalization rates than complement inhibitors, influencing treatment decisions in NMOSD management.
- B-cell depletion by rituximab may not fully prevent relapses, affecting its efficacy in NMOSD.
A panelist discusses how comparing hospitalization rates, relapse risks, and safety considerations between rituximab and other NMOSD therapies, such as complement inhibitors, can provide valuable insights to guide treatment decisions, manage healthcare costs, and optimize patient quality of life.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do hospitalization rates for rituximab compare with those seen in patients treated with complement inhibitors or other therapies?
- What implications will this have on treatment decisions?
- Please review any underlying biological or mechanistic associated with higher relapse rates reported with rituximab.
- What are some key safety considerations beyond relapse rates that may need to be addressed with long-term rituximab use in patients with NMOSD?
- What implications do relapse rates and hospitalization trends have on healthcare costs and patient quality of life in NMOSD management?
Advertisement
Related to this article
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.
New 12-month interim data showed functional gains with BBP-418 vs placebo, consistent benefit across genotype, age, and baseline pulmonary function subgroups, and a safety profile comparable to placebo.
Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.
A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.
A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.
PETUNIA, a new global pharmacovigilance study, will track pregnancy, maternal, and infant outcomes among patients with gMG exposed to nipocalimab.
In a pivotal phase 3 study, once-daily tasimelteon 20 mg shifted sleep onset 37.1 minutes earlier than placebo in adults with delayed sleep-wake phase disorder.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
ADHERE REAL Study to Assess Real-World Effectiveness of Efgartigimod in CIDP
4
Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab
5